Wells Fargo
ALXN

Wells Fargo’s Alexion Pharmaceuticals ALXN Stock Holding History

Wells Fargo’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-45,700
Closed -$1.27M – 7242
2020
Q2 		$1.27M Hold
45,700
– – ﹤0.01% 3623
2020
Q1 		$591K Buy
+45,700
New +$4.49M ﹤0.01% 3920
2019
Q1 		– Sell
-75,000
Closed -$1K – 6626
2018
Q4 		$1K Buy
+75,000
New +$8.87M ﹤0.01% 6336
2017
Q2 		– Sell
-50,000
Closed -$67K – 6553
2017
Q1 		$67K Buy
+50,000
New +$6.45M ﹤0.01% 5354

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Wells Fargo's ALXN Position: Q3 2021 in Review

Wells Fargo sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 904,290 shares — an estimated $166M sold.

Wells Fargo first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $1.14B in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Wells Fargo reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Wells Fargo sold 904,290 Alexion Pharmaceuticals shares in Q3 2021, an estimated $166M.
  • Wells Fargo first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Wells Fargo's Alexion Pharmaceuticals position peaked at $1.14B in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Wells Fargo's 13F filing for Q3 2021, filed 15 Nov 2021.